Ascendis Pharma A/S — 2019 Form 20-F Summary
Reporting period: Fiscal year ended December 31, 2019. This is an annual report, not a standalone fourth-quarter filing; the supplied text does not provide separate Q4 financial results. Financial statements are prepared under IFRS and reported in euros unless stated otherwise.
Business context
Ascendis is a clinical-stage biopharmaceutical company developing medicines using its TransCon technology platform. It had no products approved for sale and generated no product-sale revenue in 2019. Its three clinical-stage endocrine candidates were TransCon hGH for growth hormone deficiency, TransCon PTH for hypoparathyroidism, and TransCon CNP for achondroplasia. Oncology programs remained preclinical.
Financial performance and liquidity
| Metric (EUR millions, except per-share data) | 2019 | 2018 |
|---|---|---|
| Revenue | 13.4 | 10.6 |
| Research and development costs | 191.6 | 140.3 |
| General and administrative expenses | 48.5 | 25.1 |
| Operating loss | 226.7 | 154.8 |
| Net loss | 218.0 | 130.1 |
| Basic and diluted loss per share | €4.69 | €3.17 |
| Cash and cash equivalents at year-end | 598.1 | 277.9 |
| Operating cash used | 175.9 | 138.8 |
| Investing cash used | 5.2 | 2.6 |
| Financing cash provided | 493.6 | 203.3 |
- Revenue increased 26%, primarily reflecting Visen-related revenue and clinical supply sales. Revenue was collaboration-based; the filing reports no commercial product sales.
- R&D costs rose 37%, reflecting pipeline development, manufacturing validation and pre-launch inventory costs, and higher personnel and share-based compensation. G&A expenses rose 93%, including higher staffing, share-based compensation and pre-commercialization costs.
- Net loss widened by €87.9 million. Finance income declined to €17.8 million from €24.7 million, as lower foreign-exchange gains more than offset higher interest income. The company reported a €8.1 million share of loss in Visen.
- Operating cash use increased by €37.1 million. Financing cash flow included €480.3 million of net proceeds from the March 2019 ADS offering and €17.3 million from warrant exercises, partly offset by lease payments.
- At year-end, total assets were €676.7 million, total liabilities €79.6 million and equity €597.1 million. The company reported no third-party borrowings; IFRS 16 lease liabilities were €36.6 million (€30.7 million non-current and €5.9 million current).
- The company said existing cash was expected to fund projected requirements for at least 12 months from the April 2020 report date, based on its then-current operating plan. It cautioned that plans and funding needs could change.
Material changes and unusual items
- The March 2019 offering materially strengthened liquidity and increased outstanding shares to 47,985,837 at year-end, versus 42,135,448 a year earlier.
- Share-based payment expense increased to €37.5 million from €19.7 million and was a significant non-cash expense.
- IFRS 16 was adopted from January 1, 2019 using the modified retrospective approach, creating recognized right-of-use assets and lease liabilities; 2018 comparatives were not restated. Year-end right-of-use assets were €34.9 million.
- Visen, in which Ascendis holds 50%, generated €13.4 million of revenue for Ascendis in 2019, while Ascendis recognized its share of Visen’s loss. Visen received Chinese clinical-trial authorization for TransCon hGH and began a pediatric phase 3 trial.
- A 10% strengthening of the U.S. dollar against the euro was estimated to increase profit or loss and equity by €47.8 million, before tax. The company did not use foreign-exchange derivatives.
Outlook, management commentary and risks
- Management expected to submit a U.S. BLA for pediatric TransCon hGH in Q2 2020 and an EMA application in Q4 2020. These were forward-looking plans, not approvals.
- Management expected to report the one-month blinded TransCon PTH phase 2 results in mid-April 2020 and planned to begin a global phase 3 program in Q4 2020, subject to evaluation of the data. It also planned an adult GHD phase 3 study and continued dose escalation in the TransCon CNP phase 2 trial.
- The company expected expenses to rise as it advanced trials, expanded research and development, prepared for possible commercialization and built organizational capabilities. It had 330 full-time employees at year-end, including 250 in R&D.
- COVID-19 was identified as a potential threat to trial enrollment, site operations, monitoring, supply chains and access to capital. At the time the accounts were authorized, Ascendis reported no identified significant disruption to trials or manufacturer performance; the extent of future effects was uncertain.
- Key risks include clinical failure or delays, regulatory and device-review uncertainty, reliance on collaborators and single-source suppliers, manufacturing and supply constraints, reimbursement and market acceptance, competition, intellectual-property challenges, and potential need for additional financing. No material legal proceeding was identified.
- The auditor issued an unqualified opinion on the financial statements and internal controls. The audit identified clinical-trial accruals as a critical audit matter because estimating vendor progress and related accrued or prepaid costs required judgment.
Important facts for investors to verify
- Whether TransCon hGH regulatory submissions occurred on the stated timetable and what regulators requested or decided.
- Final clinical data, safety findings and trial timelines for TransCon hGH, PTH and CNP, including any COVID-19-related changes.
- Cash consumption, updated runway and financing needs relative to the company’s 2020 development and commercialization plans.
- Visen’s development progress, financial performance, and the assumptions supporting Ascendis’s recognized collaboration revenue and associate investment.
- Manufacturing capacity, supplier diversification and readiness of the devices and commercial supply chain.
- Potential dilution from warrants and future share issuance; 5,820,211 warrants were outstanding at December 31, 2019.